Form 8K Protalix Biotherapeutics Inc For: 21 May
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Protalix Biotherapeutics Inc (PLX)
The Protalix share price today is 1.990, view NYSE PLX stock exchange data. Track the latest Protalix share price with real-time updates on PLX stock performance including market cap, day range, 52-week range and dividend yield. Access PLX charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.980
2.020
52 wk Range
1.320
3.190
PLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9802.020
52 wk Range
1.3203.190
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PLX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
11.000
Upside
+452.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- Form 13G Protalix BioTherapeutics For: 30 March
- Investing.com
- Form 10Q Protalix Biotherapeutics Inc For: 13 May
- Investing.com
- Form 8K Protalix Biotherapeutics Inc For: 21 May
- Investing.com
- Form 10Q Protalix Biotherapeutics Inc For: 13 May
- Investing.com
- Form 8K Protalix Biotherapeutics Inc For: 13 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.000
(+452.76% Upside)
Protalix Biotherapeutics Inc Earnings Call Summary for Q1/2026
- Q1 2026 EPS of $0.22 beat forecast by 450%; revenue hit $33.75M vs. $18.7M expected, driven by $25M Chiesi milestone payment.
- Company swung to $18.2M net income from $3.6M loss in Q1 2025; stock rose 3.82% in premarket trading to $1.983.
- R&D expenses surged 116-125% to $5.4M due to PRX-115 phase II study; maintains strong balance sheet with $51M cash, zero debt.
- Reaffirmed 2026 revenue guidance of $78-83M (50% growth); expects significant H2 contributions as Chiesi completes Elfabrio reimbursements.
- PRX-115 RELEASE trial enrollment on track for end-2026 completion; risks include supply chain disruptions and Fabry disease market saturation.
Last Updated: 13-05-2026, 05:58 pm
Read Full TranscriptEarnings
Latest Release
13-05-2026
EPS / Forecast
0.22 / 0.04
Revenue / Forecast
33.75M / 18.7M
Compare PLX to Peers and Sector
Metrics to compare | PLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.5x | −2.3x | −0.5x | |
PEG Ratio | 0.03 | −0.08 | 0.00 | |
Price/Book | 2.4x | 3.4x | 2.6x | |
Price / LTM Sales | 2.1x | 6.4x | 3.0x | |
Upside (Analyst Target) | - | 160.1% | 58.6% | |
Fair Value Upside | Unlock | 14.2% | 10.2% | Unlock |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Protalix (PLX) Share Price Today?
The Protalix share price today is 1.990.
What is the current Protalix (PLX) share price and day range?
As of 08-06-2026, the Protalix share price is 1.990, with a previous close of 1.990. The share price has ranged from 1.980 to 2.020 today, while the 52-week range spans from 1.320 to 3.190.
What Is the Protalix Market Cap?
As of today, Protalix market cap is 160.340M.
What Is the Protalix (PLX) Share Price Target?
The average 12-month share price target for Protalix is 11.000, with a high estimate of 12 and a low estimate of 10. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +452.76% Upside potential.
What Is Protalix's Earnings Per Share (TTM)?
The Protalix EPS (TTM) is 0.193.
When Is the Next Protalix Earnings Date?
Protalix will release its next earnings report on 17-08-2026.
From a Technical Analysis Perspective, Is PLX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Protalix Trade On?
Protalix is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Protalix?
The stock symbol for Protalix is "PLX."
How Many Times Has Protalix Stock Split?
Protalix has split 2 times.
How Many Employees Does Protalix Have?
Protalix has 226 employees.
What Is the PLX After Hours Price?
PLX's last after hours stock price is 2.050, the stock has changed by 0.060, or 3.020%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.